A randomised double-blind crossover study was undertaken to compare the antiemetic efficacy of alizapride against high dose metoclopramide. A total of 32 patients on cisplatin were randomised to receive either high dose metoclopramide (7 mg kg-' day-') or alizapride (5 mg kg-' day-'). Anti-emetic responses in terms of control of vomiting episodes were similar in both regimens (59%). However, patients showed a statistically significant preference for high dose metoclopramide (P = 0.02). Side effects of both regimens were minimal. We conclude that alizapride is not superior to high dose metoclopramide in controlling cisplatin induced vomiting.
Introduction
Emesis is probably the most distressing and unpleasant side-effect of chemotherapy [1] . Some patients chose to abandon their chemotherapy rather than face the repeated agony of emesis. High dose metoclopramide has been the most widely utilised anti-emetic agent for cisplatin chemotherapy. Several reports have shown significant control of emesis with this drug [2, 3] . In the Department of Therapeutic Radiology, Singapore General Hospital, we had adopted high dose metoclopramide as our standard anti-emetic regime for patients receiving cisplatin.
Alizapride is a new substituted benzamide, developed in Europe. Its formula is N-(allyl-1-pyrrolidinyl-2) methyl methoxy 6-1-H-benzotriazole carboxamine-5. Though similar in many of its properties to metoclopamide, it displayed a significantly greater anti-emetic effect than metoclopamide in experimental animals on apomorphine and dihydroergotamine [4] . A few early clinical trials have also suggested that alizapride was superior to metoclopramide. [4, 5] .
In this study, we compared the anti-emetic efficacy of alizapride with high dose metoclopramide in patients receiving cisplatin and sought any differences in side effects of the two regimens. Table 2 ). This difference was statistically significant (P = 0.02).
There was no significant correlation between body weight or body surface area and response.
Our study showed that the response rate of control of emesis was similar in both regimens (59%), based on objective assessment of the actual number of vomiting episodes, a method used in other anti-emetic studies [6, 9, 10] .
Nausea is a difficult phenomenon to quantify. Many patients may have long periods of nausea without actual vomiting and this can be just at debilitating as vomiting itself. In an effort to encompass this effect in our assessment, we requested patients to indicate which anti-emetic regime they preferred. Analysis showed that a significant number preferred high dose metoclopramide.
In this study, high dose metoclopramide was taken as the standard regimen with which to compare alizapride, because it has been widely accepted at that time as the best for cisplatin induced vomiting [11, 12] . Alizapride was given at the recommended dose of 5 mg kg-' day-'. Higher doses have been reported to cause hypertension, arrhythmia and diarrhoea without increasing its anti-emetic efficacy.
The response rate of high dose metoclopramide of 59% was comparable with other studies using such doses [3, 12] . Alizapride gave the same response rates (59%), higher than a previously reported randomised study (34%) [7] . A high response was found in an earlier study [10] . Side effects were uncommon and mild in both regimens. Only one patient had extrapyramidal symptoms, which were controlled with parenteral diazepam.
Prior exposure to chemotherapy did not appear to prejudice the patients to subsequent cycles, as in both sequences of cross-over, the second anti-emetic regimen, regardless of it being high dose metoclopramide or alizapride, was preferred. This was unexpected as we predicted that anticipatory vomiting would have produced a reverse effect to that observed.
In conclusion, we found that alizapride did not prove to be superior to high dose metoclopramide in controlling cisplatin induced emesis, and patients preferred the latter regimen.
